Doffou E, Kamenan B A, Abrogoua D P
Laboratoire de pharmacie clinique et thérapeutique, UFR sciences pharmaceutiques et biologiques, université Felix Houphouët-Boigny, Abidjan, Cote d'Ivoire; Service de pharmacie, centre hospitalier et universitaire de Cocody, Abidjan, Cote d'Ivoire.
Laboratoire de pharmacie clinique et thérapeutique, UFR sciences pharmaceutiques et biologiques, université Felix Houphouët-Boigny, Abidjan, Cote d'Ivoire; Service de pharmacie, centre hospitalier et universitaire de Cocody, Abidjan, Cote d'Ivoire.
Ann Pharm Fr. 2022 May;80(3):340-362. doi: 10.1016/j.pharma.2021.10.001. Epub 2021 Oct 14.
This study aims to develop a tool for optimizing drug management related to clinical and therapeutic contexts of pediatric units in Côte d'Ivoire.
A list of Inappropriate prescribings (IPs) was developed from prescription review of inpatients and outpatients aged 1 month to 15 years and followed in pediatric units at 4 Teaching Hospitals of Abidjan during 16 months. A two-round Delphi method was used to validate a qualitative list of IPs by experts according to their level of agreement on a six-point Likert scale of 0-5 (0, no opinion; 5, strongly agree). Only propositions obtaining the agreement (rating 4 or 5) of>70% of experts who gave a non-zero rating for the first round and 80% for the second round were retained. Each IP of final list associated with "rationale", (justifying the inappropriateness of prescribing), and "recommendations and/or therapeutic alternative", used to elaborate items of a tool for helping to optimize drug prescriptions in pediatrics (GOPP tool).
A qualitative list of 54 IPs was drawn up from 267 Drug related problems detected after prescription review of 4992 prescription lines for 881 patients. Twenty-three (23) experts rated IPs on this list during two-round Delphi survey. At the end of survey, final list of 52 IPs was retained for development GOPP tool items. Malaria (15%), rhinitis (12%) and bacterial infectious (8%) are mainly pathologies concerned by these items.
GOPP tool developed in this study should help to improve drug management of patients in pediatric units in Côte d'Ivoire.
本研究旨在开发一种工具，以优化与科特迪瓦儿科病房临床和治疗环境相关的药物管理。
通过对阿比让4家教学医院儿科病房1个月至15岁住院和门诊患者的处方审查，制定了一份不适当处方清单，并在16个月内进行跟踪。采用两轮德尔菲法，由专家根据他们在0-5分的六点李克特量表上的同意程度（0，无意见；5，强烈同意）来验证不适当处方的定性清单。只有那些在第一轮获得非零评分的专家中超过70%同意（评分为4或5）且在第二轮获得80%同意的建议才会被保留。最终清单中的每个不适当处方都关联了“理由”（证明处方不适当）以及“建议和/或治疗替代方案”，用于编制一个有助于优化儿科药物处方的工具（GOPP工具）的项目。
在对881名患者的4992条处方行进行处方审查后检测到267个与药物相关的问题，据此制定了一份包含54个不适当处方的定性清单。23名专家在两轮德尔菲调查中对该清单上的不适当处方进行了评分。调查结束时，保留了52个不适当处方的最终清单用于编制GOPP工具项目。疟疾（15%）、鼻炎（12%）和细菌感染（8%）是这些项目主要涉及的病症。
本研究开发的GOPP工具应有助于改善科特迪瓦儿科病房患者的药物管理。
